Treating T2D by blocking fat carrier proteins

A study has identified an antibody that could have an therapeutic effect on type 2 diabetes.

The treatment method would be based on "killing the messenger", a certain fatty acid carrier, that is most likely a contributor in hyperglycemia and insulin resistance.

It was found that the antibody lowered the fasting blood sugar, and decreased insulin resistance of obese test mice. It also reduced fat mass in the liver. All as a result of blocking the fatty acid carrier called adipocyte protein 2.

The study concluded that this method could be a feasable approach in treating type 2 diabetes.